Drug-resistant colorectal cancers may soon face a precision counterstrike. When tumors develop resistance to combined KRAS-EGFR inhibition—currently one of the most promising approaches for treating KRAS-mutant colorectal cancer—they appear to exploit an unexpected cellular escape route that could be pharmacologically blocked.
The resistance mechanism involves cancer cells transforming into Paneth-like cells, a secretory cell type normally found only in healthy intestinal crypts. This cellular reprogramming allows tumors to survive dual therapy by activating alternative growth pathways. Lineage tracing experiments across mouse models, patient organoids, and clinical specimens revealed that the SMAD1 transcription factor orchestrates this transition by directly activating FGFR3, a receptor tyrosine kinase that bypasses the blocked KRAS-EGFR signaling.
This discovery exposes a fundamental vulnerability in cancer's adaptive playbook. Unlike typical resistance mutations that alter drug targets, this mechanism relies on wholesale cellular identity changes—a process called lineage plasticity that's increasingly recognized across multiple cancer types. The finding suggests that FGFR3 inhibitors could serve as precision tools to prevent or reverse this escape mechanism. In preclinical models, blocking FGFR3 both prevented the Paneth-like transition and restored sensitivity to KRAS-EGFR dual therapy.
The implications extend beyond colorectal cancer treatment. This work demonstrates how cancers co-opt normal developmental programs to survive targeted therapies, highlighting the need for anticipatory combination strategies that address both primary targets and predictable resistance pathways. For the roughly 40% of colorectal cancer patients with KRAS mutations, this could transform a promising but ultimately limited therapy into a more durable treatment approach.